跳至主要内容
临床试验/NCT00334685
NCT00334685终止2 期

[S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.

Pfizer1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2006年8月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
发起方
Pfizer
入组人数
136
试验地点
1
主要终点
The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated

研究概览

简要总结

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have pain present for more than 3 months after the healing of shingles skin rash
  • Patients at screening must have a score >/=40 mm on the pain visual analogue scale

排除标准

  • Patients with significant renal and hepatic impairment
  • Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
  • Patients with clinically abnormal electrocardiogram

研究组 & 干预措施

[S,S]-Reboxetine + Pregabalin

Experimental

干预措施: [S,S]-Reboxetine + Pregabalin (Drug)

Pregabalin

Active Comparator

干预措施: Pregabalin (Drug)

结局指标

主要结局

The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated

时间窗: Week 10

次要结局

  • The mean endpoint (week 10) sleep interference score change from baseline(Week 10)
  • Analysis of the Medical Outcomes Study Sleep Scale(Week 10)
  • Analysis of the Patient Global Impression of Change(Week 10)
  • Analysis of the Neuropathic Pain Symptom Inventory(Week 10)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

[S,S]-Reboxetine Add-On Trial | 临床试验